1. Scrip
  2. >>New Products

Sublocade Approval Grows Indivior's Opioid Addiction Franchise In Competitive Market

 
• By Mandy Jackson

US FDA approval of Sublocade, the company's once-monthly buprenorphine depot injection, may help Indivior defend its opioid addiction franchise from generics and the competing Alkermes product Vivitrol. But another new rival is expected soon – a once-monthly product from Braeburn.

ApproveOnKeyboard_1200x675

FDA approval of Indivior PLC's Sublocade (buprenorphine extended-release) gives healthcare professionals another weapon to fight the growing opioid addiction epidemic in the US. It also gives the UK-based company another product in the battle to maintain its dominant share of the opioid use disorder (OUD) market.

Indivior has seen the market share for its blockbuster OUD treatment Suboxone (buprenorphine/naloxone) sublingual film dip slightly as price-sensitive payers cut back on brand-name drugs to reduce opioid use and as sales have increased for Alkermes PLC's competing product Vivitrol (naloxone). Sublocade could give Indivior's OUD franchise the boost it needs as Suboxone and the company's sublingual tablet Subutex (buprenorphine) are challenged by generic versions of buprenorphine and Vivitrol

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Verastem Wins Approval For Novel Drug Combo In Rare Ovarian Cancer

 
• By Jessica Merrill

The novel RAF/MEK inhibitor and FAK inhibitor are the first treatment approved specifically for KRAS-mutated recurrent low-grade serious ovarian cancer (LGSOC).

Pipeline Watch: Thirteen Approvals And Ten Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 
• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

More from Scrip